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eTable 1. International Classification of Diseases codes, Ninth Revision, 16 
Clinical Modification (ICD-9-CM) codes used in the study 17 
ICD-9-CM  Descriptions 
Atrial fibrillation 
427.3 Atrial fibrillation and flutter 
Valvular heart diseases/replacement or hyperthyroidism
242 Thyrotoxicosis with or without goitre 
394.0 Mitral stenosis 
Valvular heart surgery (procedure codes) 
35.20 Open and other replacement of unspecified heart valve 
35.22 Open and other replacement of aortic valve
35.24 Open and other replacement of mitral valve 
35.26 Open and other replacement of pulmonary valve 
35.28 Open and other replacement of tricuspid valve 
Transient atrial fibrillation 
Cardiac surgery (procedure codes) 
00.5 Other cardiovascular procedures 
35 Operations on valves and septa of heart 
36 Operations on vessels of heart 
37 Other operations on heart and pericardium 
Pericarditis 
391 Rheumatic fever with heart involvement
393 Chronic rheumatic pericarditis 
420 Acute pericarditis 
423.2 Constrictive pericarditis
036.41 Meningococcal pericarditis 
074.21 Coxsackie pericarditis 
093.81 Syphilitic pericarditis 
098.83 Gonococcal pericarditis 
Myocarditis 
130.3 
391.2 Acute rheumatic myocarditis 
398.0 Rheumatic myocarditis 
422 Acute myocarditis 
429.0 Myocarditis, unspecified 
032.82 Diphtheritic myocarditis 
036.43 Meningococcal myocarditis
074.23 Coxsackie myocarditis 
093.82 Syphilitic myocarditis 
Pulmonary embolism 
415.1 Pulmonary embolism and infarction 
 18 
3 
 
eTable 1. International Classification of Diseases codes, Ninth Revision, 19 
Clinical Modification (ICD-9-CM) codes used in the study (continued) 20 
ICD-9-CM  Descriptions 
Congestive Heart Failure 
398.91 Rheumatic heart failure (congestive)  
402.01 Malignant hypertensive heart disease with heart failure 
402.11 Benign hypertensive heart disease with heart failure 
402.91 Unspecified hypertensive heart disease with heart failure 
404.01 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage I through stage IV, or unspecified 
404.03 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage V or end stage renal disease 
404.11 
Hypertensive heart and chronic kidney disease, benign, with heart failure and 
with chronic kidney disease stage I through stage IV, or unspecified 
404.13 
Hypertensive heart and chronic kidney disease, benign, with heart failure and 
chronic kidney disease stage V or end stage renal disease  
404.91 
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and with chronic kidney disease stage I through stage IV, or 
unspecified  
404.93 
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and chronic kidney disease stage V or end stage renal disease 
428 Heart failure 
Hypertension 
401 Essential hypertension
402 Hypertensive heart disease  
403 Hypertensive chronic kidney disease  
404 Hypertensive heart and chronic kidney disease  
405 Secondary hypertension 
437.2 Hypertensive encephalopathy 
Diabetes 
250 Diabetes mellitus 
Ischaemic stroke 
433.01 Occlusion and stenosis of basilar artery with cerebral infarction   
433.11 Occlusion and stenosis of carotid artery with cerebral infarction   
433.21 Occlusion and stenosis of vertebral artery with cerebral infarction   
433.31 
Occlusion and stenosis of multiple and bilateral precerebral arteries with 
cerebral infarction   
433.81 
Occlusion and stenosis of other specified precerebral artery with cerebral 
infarction 
433.91 
Occlusion and stenosis of unspecified precerebral artery with cerebral 
infarction 
434 Occlusion of cerebral arteries   
436 Acute, but ill-defined, cerebrovascular disease 
437.0 Cerebral atherosclerosis   
437.1 Other generalized ischemic cerebrovascular disease   
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eTable 1. International Classification of Diseases codes, Ninth Revision, 22 
Clinical Modification (ICD-9-CM) codes used in the study (continued) 23 
ICD-9-CM  Descriptions 
Transient ischaemic attack 
435 Transient cerebral ischemia   
Systemic embolism 
444  Arterial embolism and thrombosis 
445 Atheroembolism 
  
Vascular disease 
410-414 Ischemic heart disease 
443.8 Other specified peripheral vascular diseases 
443.9 Peripheral vascular disease, unspecified 
  
Chronic Obstructive Pulmonary Disease 
490-496 Chronic Obstructive Pulmonary Disease and Allied Conditions 
500 Coal workers' pneumoconiosis 
501 Asbestosis 
502 Pneumoconiosis due to other silica or silicates 
503 Pneumoconiosis due to other inorganic dust 
504 Pneumonopathy due to inhalation of other dust 
505 Pneumoconiosis, unspecified 
506.4 Respiratory conditions due to chemical fumes and vapors 
  
Liver disease  
456.0 Esophageal varices with bleeding 
456.1 Esophageal varices without bleeding 
456.2 Esophageal varices in diseases classified elsewhere 
571.2 Alcoholic cirrhosis of liver 
571.4 Chronic hepatitis 
571.5 Cirrhosis of liver without mention of alcohol  
571.6 Biliary cirrhosis 
572.2 Hepatic encephalopathy 
572.3 Portal hypertension 
572.4 Hepatorenal syndrome 
572.8 Other sequelae of chronic liver disease 
  
Chronic Kidney Disease 
403 Hypertensive chronic kidney disease 
404 Hypertensive heart and chronic kidney disease 
582 Chronic glomerulonephritis 
585 Chronic kidney disease (ckd) 
590.0 Chronic pyelonephritis 
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eTable 1. International Classification of Diseases codes, Ninth Revision, 25 
Clinical Modification (ICD-9-CM) codes used in the study (continued) 26 
ICD-9-CM Descriptions 
Rheumatoid arthritis and other inflammatory polyarthropathies 
710.0 Systemic lupus erythematosus 
710.1 Systemic sclerosis 
710.4 Polymyositis 
714.0 Rheumatoid arthritis 
714.1 Felty's syndrome 
714.2 Other rheumatoid arthritis with visceral or systemic involvement 
714.81 Rheumatoid lung 
725 Polymyalgia rheumatica 
  
Bone tumour  
170 Malignant neoplasm of bone and articular cartilage 
  
Epilepsy/seizure 
333.2 Myoclonus 
345 Epilepsy and recurrent seizures 
780.33 Post traumatic seizures 
780.39 Other convulsions 
  
Osteoporosis  
733.0 Osteoporosis 
  
Fractures 
805 Fracture of vertebral column without mention of spinal cord injury 
812 Fracture of humerus 
813 Fracture of radius and ulna 
814 Fracture of carpal bone(s) 
820 Fracture of neck of femur 
  
History of falls  
781.2 Abnormality of gait 
781.3 Lack of coordination 
781.99 Other symptoms involving nervous and musculoskeletal systems 
V15.88 History of fall 
E880-E888 Accidental Falls 
 27 
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eTable 1. International Classification of Diseases codes, Ninth Revision, 30 
Clinical Modification (ICD-9-CM) codes used in the study (continued) 31 
ICD-9-CM Descriptions 
Motor vehicle accidents 
E800-E807 Railway Accidents 
E810-E819 Motor Vehicle Traffic Accidents 
E820-E825 Motor Vehicle Nontraffic Accidents 
E826-E829 Other Road Vehicle Accidents 
E830-E831 Water Transport Accidents 
E840-E845 Air And Space Transport Accidents 
E846-E848 Vehicle Accidents, Not Elsewhere Classifiable 
  
Accidental falls from height  
E880 Accidental fall on or from stairs or steps 
E881 Accidental fall on or from ladders or scaffolding 
E882 Accidental fall from or out of building or other structure 
E883 Accidental fall into hole or other opening in surface 
E884.0 Accidental fall from playground equipment 
E884.1 Accidental fall from cliff 
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eTable 2. Baseline patient characteristics for the analysis with 5% trimming of propensity score 32 
Before propensity-score matching After propensity-score matching 
 Dabigatran Warfarin 
Standardized 
differencea Dabigatran Warfarin 
Standardized 
differencea 
N 3298 6981  2799 4207  
Age, mean ± SD 74.3 ± 10.1 72.1 ± 11.7 0.20 73.6 ± 9.9 72.9 ± 10.6 0.07 
Female 1685 (51.1) 3227 (46.2) 0.10 1364 (48.7) 2008 (47.7) 0.02 
Baseline medical conditions    
CHADS2, mean ± SD 2.1 ± 1.5 2.1 ± 1.6 0.02 2.0 ± 1.5 2.0 ± 1.6 0.02 
CHA2DS2-VASc, mean ± SD 3.4 ± 2.2 3.3 ± 2.2 0.04 3.2 ± 2.2 3.2 ± 2.2 0.02 
Congestive heart failure 689 (20.9) 2205 (31.6) -0.24 589 (21.0) 1052 (25.0) -0.09 
Prior ischemic stroke/transient ischemic attack 1116 (33.8) 2073 (29.7) 0.09 863 (30.8) 1217 (28.9) 0.04 
Chronic Obstructive Pulmonary Disease 274 (8.3) 581 (8.3) <0.001 222 (7.9) 353 (8.4) -0.02 
Diabetes mellitus 997 (30.2) 1982 (28.4) 0.04 786 (28.1) 1144 (27.2) 0.02 
History of falls 518 (15.7) 931 (13.3) 0.07 410 (14.6) 593 (14.1) 0.02 
History of fractures 237 (7.2) 446 (6.4) 0.03 198 (7.1) 279 (6.6) 0.02 
Liver disease 16 (0.5) 44 (0.6) -0.02 12 (0.4) 27 (0.6) -0.03 
Osteoporosis 40 (1.2) 69 (1.0) 0.02 28 (1.0) 39 (0.9) 0.01 
Rheumatoid arthritis and other inflammatory 
polyarthropathies 
14 (0.4) 45 (0.6) -0.03 12 (0.4) 18 (0.4) <0.001 
Chronic kidney disease 94 (2.9) 536 (7.7) -0.22 31 (1.1) 72 (1.7) -0.05 
Baseline medication use       
ACE inhibitor or ARB 1552 (47.1) 3332 (47.7) -0.01 1264 (45.2) 1940 (46.1) -0.02 
Beta-blocker 2011 (61.0) 4028 (57.7) 0.07 1649 (58.9) 2428 (57.7) 0.02 
Bisphonsphonates 43 (1.3) 54 (0.8) 0.05 15 (0.5) 25 (0.6) -0.01 
Systemic glucocorticoid 213 (6.5) 583 (8.4) -0.07 188 (6.7) 314 (7.5) -0.03 
Antidepressants 128 (3.9) 224 (3.2) 0.04 95 (3.4) 127 (3.0) 0.02 
Values are expressed as frequency (%) unless otherwise specified. Abbreviations: SD, standard deviation; CHADS2, congestive heart failure, hypertension, age ≥75 years, 33 
diabetes mellitus, prior stroke/transient ischemic attack/systemic embolism (doubled); CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (doubled), 34 
diabetes mellitus, age 65–74 years, prior stroke/transient ischemic attack/systemic embolism (doubled), vascular disease, and sex category (female); CHA2DS2-VASc score 35 
ranges from 0-9, where a higher score indicates a higher risk for stroke; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. 36 
aStandardized difference is the difference in mean or proportion of covariates in dabigatran group versus warfarin group divided by the pooled standard deviation; standardized 37 
difference <0.2 indicates a negligible difference in covariates between treatment groups. 38 
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eTable 3. Baseline patient characteristics for the post-hoc analysis for dabigatran versus non-treated patients 39 
  Before propensity-score matching After propensity-score matching 
  Dabigatran Non-treated 
Standardized 
differencea Dabigatran Non-treated 
Standardized 
differencea 
N 3298 30 900   2829 5556   
Age, mean ± SD 74.3 ± 10.1 78.4 ± 12.6 -0.37 74.2 ± 10.1 74.5 ± 13.4 -0.02 
Female 1685 (51.1) 15902 (51.5) -0.01 1462 (51.7) 2913 (52.4) -0.02 
Baseline medical conditions             
CHADS2, mean ± SD 2.1 ± 1.5 1.9 ± 1.6 0.15 2.1 ± 1.5 2.2 ± 1.7 -0.02 
CHA2DS2-VASc, mean ± SD 3.4 ± 2.2 3.2 ± 2.4 0.10 3.4 ± 2.2 3.5 ± 2.5 -0.03 
Congestive heart failure 689 (20.9) 8021 (26.0) -0.12 586 (20.7) 1107 (19.9) 0.02 
Prior ischemic stroke/ transient ischemic attack 1116 (33.8) 5509 (17.8) 0.37 963 (34.0) 1789 (32.2) 0.04 
Chronic Obstructive Pulmonary Disease 274 (8.3) 4363 (14.1) -0.18 227 (8.0) 426 (7.7) 0.01 
Diabetes mellitus 997 (30.2) 7680 (24.9) 0.12 871 (30.8) 1697 (30.5) 0.01 
History of falls 518 (15.7) 7648 (24.8) -0.23 431 (15.2) 866 (15.6) -0.01 
History of fractures 237 (7.2) 4113 (13.3) -0.20 198 (7.0) 383 (6.9) <0.001
Liver disease 16 (0.5) 341 (1.1) -0.07 14 (0.5) 30 (0.5) -0.01 
Osteoporosis 40 (1.2) 629 (2.0) -0.07 35 (1.2) 60 (1.1) 0.01 
Rheumatoid arthritis and other inflammatory 
polyarthropathies 14 (0.4) 231 (0.7) -0.04 12 (0.4) 28 (0.5) -0.01 
Chronic kidney disease 94 (2.9) 2994 (9.7) -0.28 80 (2.8) 169 (3.0) -0.01 
Baseline medication use             
ACE inhibitor or ARB 1552 (47.1) 9044 (29.3) 0.37 1347 (47.6) 2626 (47.3) 0.01 
Beta-blocker 2011 (61.0) 9710 (31.4) 0.62 1737 (61.4) 3398 (61.2) 0.00
Bisphonsphonates 43 (1.3) 317 (1.0) 0.03 40 (1.4) 85 (1.5) -0.01 
Systemic glucocorticoid 213 (6.5) 2977 (9.6) -0.12 185 (6.5) 374 (6.7) -0.01 
Antidepressants 128 (3.9) 1002 (3.2) 0.03 106 (3.7) 205 (3.7) 0.003 
Values are expressed as frequency (%) unless otherwise specified. Abbreviations: SD, standard deviation; CHADS2, congestive heart failure, hypertension, age ≥75 years, 40 
diabetes mellitus, prior stroke/transient ischemic attack/systemic embolism (doubled); CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (doubled), 41 
diabetes mellitus, age 65–74 years, prior stroke/transient ischemic attack/systemic embolism (doubled), vascular disease, and sex category (female); CHA2DS2-VASc score 42 
ranges from 0-9, where a higher score indicates a higher risk for stroke; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. 43 
aStandardized difference is the difference in mean or proportion of covariates in dabigatran group versus warfarin group divided by the pooled standard deviation; standardized 44 
difference <0.2 indicates a negligible difference in covariates between treatment groups. 45 
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eTable 4. Results for the post-hoc analysis for dabigatran versus non-treated patients 46 
 Dabigatran 
 Non-treated  Dabigatran vs. Non-treated 
 N 
No. of 
cases/py 
incidence  
per 100 py N 
No. of 
cases/py 
incidence  
per 100 py ARD (95% CI) IRR (95% CI) p 
Before PS matching 3298 34/4594 0.7 30 900 1368/78 732 1.7 -0.98 (-0.68 to -1.18) 0.43 (0.30 to 0.60) <.001 
After PS matching 2829 32/4314 0.7 5556 173/13 078 1.3 -0.62 (-0.25 to -0.87) 0.52 (0.33 to 0.81) .002 
Abbreviations: py: person-years; ARD: absolute risk difference per 100 person-years; IRR, incidence rate ratio; CI, confidence interval; PS, propensity score.   47 
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 48 
eFigure 1. Distribution of propensity score before and after matching for dabigatran versus warfarin patients. The curves 49 
illustrate the distribution of the probability of a patient receiving dabigatran conditional on the observed patient characteristics (i.e. 50 
propensity score). Such probability was calculated using logistic regression in which dabigatran treatment (yes/no) was the 51 
dependent variable and the observed patient characteristics were the covariates. 52 
  53 
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 54 
eFigure 2. Selection of non-treated patients in the post-hoc analysis 55 
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56 
eFigure 3. Distribution of propensity score before and after matching in the post-hoc analysis for dabigatran versus non-57 
treated patients. The curves illustrate the distribution of the probability of a patient receiving dabigatran conditional on the 58 
observed patient characteristics (i.e. propensity score). Such probability was calculated using logistic regression in which 59 
dabigatran treatment (yes/no) was the dependent variable and the observed patient characteristics were the covariates. 60 
 61 
